Biblio

Export 111 results:
Author Title [ Type(Desc)] Year
Filters: Keyword is Biomarkers  [Clear All Filters]
Journal Article
L. Wu, Liu, J., Feng, X., Dong, J., Qin, W., Liu, Y., Wang, J., Lu, J., Chen, K., Wang, Y., and Jia, J., “11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.”, J Alzheimers Dis, vol. 61, no. 2, pp. 613-618, 2018.
L. Chen, Shen, Q., Xu, S., Yu, H., Pei, S., Zhang, Y., He, X., Wang, Q. Z., and Li, D., “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
H. Li, Zhu, H., Wallack, M., Mwamburi, M., Abdul-Hay, S. O., Leissring, M. A., and Qiu, W. Qiao, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
H. - H. Tsou, Hsu, W. - C., Fuh, J. - L., Chen, S. - P., Liu, T. - Y., and Wang, H. - T., “Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 571-580, 2018.
R. C. Petersen, Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., and Weiner, M. W., “Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.”, Neurology, vol. 74, no. 3, pp. 201-9, 2010.
T. E. Golde, Schneider, L. S., and Koo, E. H., “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
M. Berger, Cooter, M., Roesler, A. S., Chung, S., Park, J., Modliszewski, J. L., VanDusen, K. W., J Thompson, W., Moseley, A., Devinney, M. J., Smani, S., Hall, A., Cai, V., Browndyke, J. N., Lutz, M. W., and Corcoran, D. L., “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
C. - C. Yang, Chiu, M. - J., Chen, T. - F., Chang, H. - L., Liu, B. - H., and Yang, S. - Y., “Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1323-1332, 2018.
M. Siotto, Simonelli, I., Pasqualetti, P., Mariani, S., Caprara, D., Bucossi, S., Ventriglia, M., Molinario, R., Antenucci, M., Rongioletti, M., Rossini, P. Maria, and Squitti, R., “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
S. J. Teipel, Dyrba, M., Ballarini, T., Brosseron, F., Bruno, D., Buerger, K., Cosma, N. - C., Dechent, P., Dobisch, L., Düzel, E., Ewers, M., Fliessbach, K., Haynes, J. D., Janowitz, D., Kilimann, I., Laske, C., Maier, F., Metzger, C. D., Munk, M. H., Peters, O., Pomara, N., Preis, L., Priller, J., Rámirez, A., Roy, N., Scheffler, K., Schneider, A., Schott, B. H., Spottke, A., Spruth, E. J., Wagner, M., Wiltfang, J., Jessen, F., and Heneka, M. T., “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
N. Shu Ning Teoh, Gyanwali, B., Lai, M. K. P., Chai, Y. Ling, Chong, J. R., Chong, E. Jun Yi, Chen, C., Tan, C. Seng, and Hilal, S., “Association of Interleukin-6 and Interleukin-8 with Cognitive Decline in an Asian Memory Clinic Population.”, J Alzheimers Dis, vol. 92, no. 2, pp. 445-455, 2023.
W. M. A. D. Bino Fernando, Rainey-Smith, S. R., Gardener, S. L., Villemagne, V. L., Burnham, S. C., S Macaulay, L., Brown, B. M., Gupta, V. Bala, Sohrabi, H. R., Weinborn, M., Taddei, K., Laws, S. M., Goozee, K., Ames, D., Fowler, C., Maruff, P., Masters, C. L., Salvado, O., Rowe, C. C., and Martins, R. N., “Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1589-1598, 2018.
T. Dziedzic, Pera, J., Klimkowicz-Mrowiec, A., Mroczko, B., and Slowik, A., “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.
A. Mishima, Nihashi, T., Ando, Y., Kawai, H., Kato, T., Ito, K., and Terasawa, T., “Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 161-74, 2016.
D. R. Galasko, Grill, J. D., Lingler, J. H., and Heidebrink, J. L., “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
T. K. Karikari, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
H. - F. Wang, Wan, Y., Hao, X. - K., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Tan, L., Zhang, D. - Q., Tan, L., and Yu, J. - T., “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
D. Renard, Collombier, L., Demattei, C., Wacongne, A., Charif, M., Ayrignac, X., Azakri, S., Gaillard, N., Boudousq, V., Lehmann, S., de Champfleur, N. Menjot, and Thouvenot, E., “Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.

Pages